Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharming Group N.V.

8.51
+0.0000
Post-market: 8.510.00000.00%16:05 EDT
Volume:150.00
Turnover:1.29K
Market Cap:582.03M
PE:-47.28
High:8.51
Open:8.51
Low:8.51
Close:8.51
Loading ...

Company Profile

Company Name:
Pharming Group N.V.
Exchange:
NASDAQ
Establishment Date:
1988
Employees:
404
Office Location:
Darwinweg 24,Leiden,Zuid-Holland,Netherlands
Zip Code:
2333 CR
Fax:
31 71 524 7445
Introduction:
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Directors

Name
Position
Sijmen de Vries
Chief Executive Officer,Executive Director
Deborah Jorn
Vice Chairperson
Paul Sekhri
Chairperson
Barbara Yanni
Director
Jabine van der Meijs
Director
Leonard Kruimer
Director
Mark Pykett
Director
Steven Baert
Director

Shareholders

Name
Position
Sijmen de Vries
Chief Executive Officer,Executive Director
Jeroen Wakkerman
Chief Financial Officer
Anurag Relan
Chief Medical Officer
Mireille Sanders
Chief Operations Officer
Ruud van Outersterp
Chief Ethics and Compliance Officer
Stephen Toor
Chief Commercial Officer and GM Americas